BridgeBio Pharma stays a strong buy with key drug approvals and $1B funding boost.

BridgeBio Pharma remains a strong buy due to regulatory approvals for its drug acoramidis and positive clinical data for infigratinib in achondroplasia. The company expects $180.6 million in U.S. net product revenue by Q1 2026 and targets a $2.9 billion global market with its pipeline expansion. A recent $1 billion preferred equity raise secures funding for at least 12 months, supporting ongoing NDA submissions and commercialization efforts.